DiaMedica's DM199, a recombinant human tissue kallikrein-1, demonstrates promising potential in acute ischemic stroke treatment by enhancing collateral circulation and stimulating angiogenesis.
DiaMedica Therapeutics modified its ReMEDy2 trial for acute ischemic stroke, including thrombolytic non-responders and increasing interim analysis sample size to 200 subjects.